<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465669</url>
  </required_header>
  <id_info>
    <org_study_id>Healing Stent</org_study_id>
    <nct_id>NCT04465669</nct_id>
  </id_info>
  <brief_title>Heterogeneity of Neointimal Healing Following Biodegradable-polymer Drug-Eluting Coronary Stent Implantation</brief_title>
  <acronym>Healing</acronym>
  <official_title>Heterogeneity of Neointimal Healing Following Biodegradable-polymer Drug-Eluting Coronary Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is a comparative evaluation of Orsiro stent and of Resolute
      Integrity stent in terms of the extent of neointima formation at 3 months after implantation
      using optical coherence tomography (OCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 50 patients with clinical evidence of ischemic heart disease and / or a positive
      functional study and documented stable angina pectoris (Canadian cardiovascular society
      classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-novo, native,
      previously unstented vessel in Tyumen Cardiology Center,will be randomly assigned undergoing
      implantation of Orsiro stent or Resolute Integrity stent (in a 1:1 ratio).

      All of the patients will receive 12 months dual antiplatelet therapy and they will be
      followed (at the outpatient clinic) for up to 1 year. The follow-up visits will be conducted
      at 3 months (including angiographic/OCT investigation), and 1 year post percutaneous coronary
      intervention(PCI),in order to observe the Primary Endpoint and Secondary Endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>About 50 patients with clinical evidence of ischemic heart disease and / or a positive functional study and documented stable angina pectoris (Canadian cardiovascular society classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-novo, native, previously unstented vessel in Tyumen Cardiology Center,will be randomly assigned undergoing implantation of Orsiro stent or Resolute Integrity stent (in a 1:1 ratio).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heterogeneous neointimal healing</measure>
    <time_frame>3 months</time_frame>
    <description>Endothelial coverage by Heterogeneous neointima of the stent struts assessed by optical coherence tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malapposed stent struts</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of malapposed stent struts by optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal growth</measure>
    <time_frame>3 months</time_frame>
    <description>Neointimal thickness by optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic reference vessel diameter</measure>
    <time_frame>3 months</time_frame>
    <description>Reference diameter of coronary artery by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical composite endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death/Target vessel MI/Clinically indicated TLR All death/All MI/All TVR (including TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Definite stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncovered stent struts</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of uncovered stent struts by optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic minimal lumen diameter</measure>
    <time_frame>3 months</time_frame>
    <description>Minimal lumen diameter of coronary artery by QCA;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic diameter stenosis</measure>
    <time_frame>3 months</time_frame>
    <description>Percent diameter stenosis by QCA;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>3 months</time_frame>
    <description>Binary restenosis by QCA;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic late lumen loss</measure>
    <time_frame>3 months</time_frame>
    <description>Late lumen loss by QCA;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Stable Angina Pectoris</condition>
  <condition>Silent Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of a Orsiro® biolimus a9 eluting coronary stent (drug-eluting stent, DES)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Integrity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of a Resolute Integrity® zotarolimus eluting coronary stent (drug-eluting stent, DES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro stents</intervention_name>
    <description>Percutaneous coronary intervention with implantation of either:
a Orsiro® biolimus a9 eluting coronary stent</description>
    <arm_group_label>Orsiro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Integrity® stents</intervention_name>
    <description>Percutaneous coronary intervention with implantation of either:
a Resolute Integrity® zotarolimus eluting coronary stent</description>
    <arm_group_label>Resolute Integrity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years;

          -  Patients with symptoms of stable angina and/or presence of a positive functional test
             for ischemia;

          -  Patient is eligible for percutaneous coronary intervention (PCI);

          -  Patient has been informed of the nature of the study and agrees to its provisions and
             has provided written informed consent as approved by the Ethical Committee of the
             respective clinical site.

        Exclusion Criteria:

          -  Target lesion involving a bifurcation with a side branch ≥2.0 mm in diameter;

          -  Target lesion located in the left main stem;

          -  Target lesion is located or supplied by an arterial or venous bypass graft;

          -  Lesion located very distally, difficult to be imaged by OCT;

          -  Co-morbidities that could interfere with completion of study procedures, or life
             expectancy less than 1 year;

          -  Participating in another investigational drug or device trial that has not completed
             the primary endpoint or would interfere with the endpoints of this study;

          -  Patient underwent target vessel revascularization with a DES;

          -  Patient presenting with acute myocardial infarction with ST elevation;

          -  Cerebrovascular accident within the past 12 months;

          -  Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);

          -  Patient receiving oral anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bessonov S Ivan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tyumen Cardiology Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanislav Sapozhnikov</last_name>
    <phone>+79091919191</phone>
    <email>stas_ss@bk.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislav S Sapozhnikov</last_name>
      <phone>+79091919191</phone>
      <email>stas_ss@bk.ru</email>
    </contact>
    <contact_backup>
      <last_name>Ivan S Bessonov</last_name>
      <phone>+79068237755</phone>
      <email>ivanbessnv@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT04465669/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

